Incendia Therapeutics Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 19

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $13.3M

  • Investors
  • 11

Incendia Therapeutics General Information

Description

Operator of a novel therapeutics company intended to invent a class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The company designs a portfolio of drug candidates that interplay between cancer cells and their surrounding microenvironment, which is relevant in drug development to build barriers that shield the immune system from attacks, and one approach breaks these barriers to overcome recalcitrant cancers that are based on rigorous, ground-breaking research, enabling doctors to treat the right patients at the right time.

Contact Information

Formerly Known As
Parthenon Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 40 Guest Street
  • Boston, MA 02135
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 40 Guest Street
  • Boston, MA 02135
  • United States
+1 (617)

Incendia Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Incendia Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC 09-Sep-2025 $13.3M Completed Generating Revenue
2. Early Stage VC (Series A1) 01-May-2023 Completed Clinical Trials - Phase 1
1. Early Stage VC (Series A) 13-Aug-2021 $65M $65M Completed Clinical Trials - Phase 1
To view Incendia Therapeutics’s complete valuation and funding history, request access »

Incendia Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A-1
Series A-3
Series A-2 60,597 $0.000100 $3.37 $3.37 1x $3.37 0.14%
To view Incendia Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Incendia Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a novel therapeutics company intended to invent a class of anti-cancer therapies that reprogram the tumor mi
Drug Discovery
Boston, MA
19 As of 2026

Hampton, NJ
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Incendia Therapeutics Competitors (2)

One of Incendia Therapeutics’s 2 competitors is Celldex, a Formerly VC-backed company based in Hampton, NJ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Celldex Formerly VC-backed Hampton, NJ
AVEO Oncology Formerly VC-backed Boston, MA
You’re viewing 2 of 2 competitors. Get the full list »

Incendia Therapeutics Patents

Incendia Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023379591-A1 Methods of treating cancer using anti-ddr1 antibodies Pending 16-Nov-2022
EP-4619441-A1 Methods of treating cancer using anti-ddr1 antibodies Pending 16-Nov-2022
US-20260184795-A1 Methods of treating cancer using anti-ddr1 antibodies Pending 16-Nov-2022
WO-2024107899-A1 Methods of treating cancer using anti-ddr1 antibodies Inactive 16-Nov-2022
AU-2023379587-A1 Methods of treating cancer using anti-ddr1 antibodies and immune checkpoint inhibitors Pending 16-Nov-2022 C07K16/2851
To view Incendia Therapeutics’s complete patent history, request access »

Incendia Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Incendia Therapeutics Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
abrdn Healthcare Investors Hedge Fund Minority
Aberdeen Investments (Scotland) Asset Manager Minority
Alexandria Venture Investments Venture Capital Minority
Breakout Ventures Venture Capital Minority
Creacion Ventures Venture Capital Minority
You’re viewing 5 of 11 investors. Get the full list »

Incendia Therapeutics FAQs

  • When was Incendia Therapeutics founded?

    Incendia Therapeutics was founded in 2019.

  • Where is Incendia Therapeutics headquartered?

    Incendia Therapeutics is headquartered in Boston, MA.

  • What is the size of Incendia Therapeutics?

    Incendia Therapeutics has 19 total employees.

  • What industry is Incendia Therapeutics in?

    Incendia Therapeutics’s primary industry is Drug Discovery.

  • Is Incendia Therapeutics a private or public company?

    Incendia Therapeutics is a Private company.

  • What is Incendia Therapeutics’s current revenue?

    The current revenue for Incendia Therapeutics is .

  • How much funding has Incendia Therapeutics raised over time?

    Incendia Therapeutics has raised $78.3M.

  • Who are Incendia Therapeutics’s investors?

    abrdn Healthcare Investors, Aberdeen Investments (Scotland), Alexandria Venture Investments, Breakout Ventures, and Creacion Ventures are 5 of 11 investors who have invested in Incendia Therapeutics.

  • Who are Incendia Therapeutics’s competitors?

    Celldex and AVEO Oncology are competitors of Incendia Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process